Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from October 21, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 19, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$85.90 Published $96.25 Target $108.83 Window close $112.90 Peak
$83.57 – $85.53Entry zone — fair-value band
$85.90Published — price the day we called it
$96.25Target — the price the thesis aimed for
$112.90Peak — highest point inside the window, not a realized return
$108.83Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 31 days.

Peak price
$112.90
peak on January 8, 2026 — not a realized return
Peak gain
+31.4%
peak, from the publication price
Window close
$108.83
end-of-window price, context only
Days to target
31
Window
October 21, 2025 – January 19, 2026

The thesis — published October 21, 2025

Predicted growth
+13%
over the measurement window
Target price
$96.25
the price the thesis aimed for
Entry zone
$83.57 – $85.53
the fair-value band we waited for
Price at publication
$85.90
published October 21, 2025
Confidence
66%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a steady grower that can handle rough markets. The company confirmed a $3B factory in Virginia and shared helpful results for its new vaccine, which should lift supply and strengthen its vaccine lineup. A common momentum gauge is a bit weak, but the recent average price trend is edging up, hinting the stock may be settling. Gradually buying over the next 0-3 months fits as healthcare sentiment improves.

Primary drivers

  • $3B Virginia factory adds capacity and supports future product demand.
  • Positive CAPVAXIVE results strengthen the case for Merck's next vaccine.
  • Investor mood is firm; trading suggests the price may be settling.
  • Stable healthcare demand can help in uncertain economic periods.

How it played out

MRK: target reached in 31 days

Lyra published MRK at $85.90 on October 21, 2025, with expected growth of 13%. The thesis pointed to a $3B Virginia factory, positive CAPVAXIVE results, steadier trading, and stable healthcare demand in uncertain markets. It also noted one weak momentum gauge.

Inside the window from October 21, 2025 to January 19, 2026, MRK reached the $96.25 target in 31 days. The stock later peaked at $112.90 on January 8, 2026, with a 31.4% gain. It ended at $108.83. The thesis played out, and the move went beyond the target.

What happened during the window

On October 30, 2025, Merck reported third-quarter sales of $17.28 billion and adjusted earnings of $2.58 per share. The company also raised its 2025 profit guidance, while narrowing its sales outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals